Gilead Sciences Inc. (NASDAQ:GILD) announced that it has elected to settle its conversion obligations in connection with any 1.00% Senior Convertible Notes due 2014 (the “Notes”) submitted for conversion on or after February 1 2014 entirely in cash. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -4.01% in last session and finished the day at $68.55. Traded volume was 29.25million shares in the last session and the average volume of the stock remained 12.71million shares. The beta of the stock remained 0.55. Gilead Sciences, Inc. (NASDAQ:GILD) insider ownership is 0.50%.

Exact Sciences Corp. (NASDAQ:EXAS) announced that the U.S. Food and Drug Administration’s (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determined by a unanimous vote of 10 to zero that Exact Sciences Corporation (NASDAQ:EXAS) has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard®, the company’s stool-based DNA (sDNA), non-invasive colorectal cancer screening test. EXACT Sciences Corporation (NASDAQ:EXAS) dropped -6.47 percent to $12.86 Friday on volume of 9.32million shares. The intra-day range of the stock was $12.52 to $14.60. EXACT Sciences Corporation (NASDAQ:EXAS) has a market capitalization of $915.65million.

Endocyte, Inc. (NASDAQ:ECYT) announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $21.00 per share. The gross proceeds to Endocyte, Inc. (NASDAQ:ECYT) from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Endocyte, Inc. (NASDAQ:ECYT), will be approximately $94.5 million. Endocyte, Inc. (NASDAQ:ECYT)’s stock on Mar 28, 2014 reported a decrease of -4.81% to the closing price of $21.96. Its fifty two weeks range is $8.18-$33.70. The total market capitalization recorded $796.43million. The overall volume in the last trading session was 7.26million shares. In its share capital, ECYT has 36.15million outstanding shares.

Belviq, the new weight-loss drug from Arena Pharmaceuticals Inc. (NASDAQ:ARNA), has begun testing in a Phase 2 clinical trial to help smokers kick the habit. San Diego’s Arena said in a Thursday regulatory filing that it is conducting the clinical trial along with its marketing partner, the Japanese drugmaker Eisai. On Friday, shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -3.17% to close the day at $6.10. Company return on investment (ROI) is -13.90% and its monthly performance is recorded as -9.90%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly revenue growth is 2.01%.